AKT1 and prostate cancer: In addition, in human prostate cancer cells investigators revealed that epigallocatechin‐3‐gallate (EGCG) results in the inhibition of VM by suppressing the Twist/VE‐cadherin/AKT pathways in human PC‐3 cells [70].